Kura Oncology (NASDAQ:KURA) Hits New 52-Week Low - Should You Sell?

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $6.79 and last traded at $7.33, with a volume of 1358259 shares. The stock had previously closed at $7.24.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Bank of America lowered their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a report on Friday, November 22nd. BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. StockNews.com upgraded shares of Kura Oncology from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Scotiabank reduced their target price on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Kura Oncology currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.50.

Remove Ads

Kura Oncology Stock Up 1.2 %

The company has a market capitalization of $591.93 million, a PE ratio of -3.11 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company's 50-day moving average is $7.97 and its 200 day moving average is $13.20.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analysts' expectations of $57.96 million. As a group, analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock valued at $92,307. Corporate insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Kura Oncology

Hedge funds have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Kura Oncology by 7.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company's stock worth $1,147,000 after acquiring an additional 9,050 shares during the period. Woodline Partners LP grew its stake in shares of Kura Oncology by 20.6% during the 4th quarter. Woodline Partners LP now owns 172,704 shares of the company's stock valued at $1,504,000 after purchasing an additional 29,497 shares during the period. Velan Capital Investment Management LP purchased a new stake in shares of Kura Oncology during the 4th quarter valued at about $1,306,000. Squarepoint Ops LLC bought a new position in shares of Kura Oncology in the 4th quarter worth approximately $799,000. Finally, Two Sigma Advisers LP boosted its holdings in shares of Kura Oncology by 147.1% in the fourth quarter. Two Sigma Advisers LP now owns 242,200 shares of the company's stock worth $2,110,000 after buying an additional 144,201 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.